Table 1.
Clinical and pathological characteristics of the studied cohort.
| Patient’s Characteristics | Mean ± SD | N |
|---|---|---|
| Age (years) | 63.5 ± 6.35 | 97 |
| Prostatic Volume (c.c) | 47.49 ± 23.09 | 97 |
| Testosterone (nmol/L) | 14.37 ± 5.07 | 97 |
| Total PSA (ng/mL) | 9.57 ± 7.92 | 97 |
| N (%) | ||
| BMI (kg/m2) | <25 | 25 (25.8) |
| 25 ≤ x ≤ 29.99 | 50 (51.5) | |
| ≥30 | 19 (19.6) | |
| Total PSA (ng/mL) | ||
| <4 | 8 (8.2) | |
| 4 ≤ x < 10 | 60 (61.9) | |
| ≥ 10 | 29 (29.9) | |
| ISUP-GG | ||
| Low Risk | Group I | 32 (33.0) |
| Group II | 25 (25.8) | |
| High Risk | Group III | 23 (23.7) |
| Group IV | 10 (10.3) | |
| Group V | 7 (7.2) | |
| T pathological stage | ||
| ≤T2a | 68 (70.1) | |
| T3,T4 | 29 (29.9) | |
| N pathological stage | ||
| NX | 57 (58.8) | |
| N0 | 34 (35.1) | |
| N1 | 6 (6.2) | |
Abbreviations: BMI, body mass index; ISUP-GG, International Society of Urological Pathology Gleason Grade groups based on the Gleason score as follows: (Gleason score ≤ 6—group I; 3 + 4 = 7 group II; 4 + 3 = 7 group III; 4 + 4 = 8—group IV; and 9–10—group V); PSA, prostate-specific antigen; T stage, Tumor category; N node, category. The bolded words differentiate the clinical and pathological characteristics from the rest of the table.